207 related articles for article (PubMed ID: 34803378)
21. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
22. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
23. Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes.
Su J; Sun H; Meng Q; Zhang P; Yin Q; Li Y
Theranostics; 2017; 7(3):523-537. PubMed ID: 28255347
[TBL] [Abstract][Full Text] [Related]
24. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth].
Zhang ZQ; Zhong CL; Zhao X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317
[TBL] [Abstract][Full Text] [Related]
25. Peptide mediated active targeting and intelligent particle size reduction-mediated enhanced penetrating of fabricated nanoparticles for triple-negative breast cancer treatment.
Hu G; Chun X; Wang Y; He Q; Gao H
Oncotarget; 2015 Dec; 6(38):41258-74. PubMed ID: 26517810
[TBL] [Abstract][Full Text] [Related]
26. Design and characterization of dual responsive mesoporous silica nanoparticles for breast cancer targeted therapy.
Bhavsar DB; Patel V; Sawant KK
Eur J Pharm Sci; 2020 Sep; 152():105428. PubMed ID: 32553643
[TBL] [Abstract][Full Text] [Related]
27. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
[TBL] [Abstract][Full Text] [Related]
28. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
29. Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells.
Pullan J; Dailey K; Bhallamudi S; Feng L; Alhalhooly L; Froberg J; Osborn J; Sarkar K; Molden T; Sathish V; Choi Y; Brooks A; Mallik S
ACS Appl Bio Mater; 2022 May; 5(5):2163-2175. PubMed ID: 35417133
[TBL] [Abstract][Full Text] [Related]
30. Platelet-camouflaged nanococktail: Simultaneous inhibition of drug-resistant tumor growth and metastasis via a cancer cells and tumor vasculature dual-targeting strategy.
Jing L; Qu H; Wu D; Zhu C; Yang Y; Jin X; Zheng J; Shi X; Yan X; Wang Y
Theranostics; 2018; 8(10):2683-2695. PubMed ID: 29774068
[TBL] [Abstract][Full Text] [Related]
31. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
[TBL] [Abstract][Full Text] [Related]
32. ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy.
Zhou J; Li K; Zang X; Xie Y; Song J; Chen X
Int J Nanomedicine; 2023; 18():1381-1397. PubMed ID: 36987427
[TBL] [Abstract][Full Text] [Related]
33. iRGD-decorated reduction-responsive nanoclusters for targeted drug delivery.
Hu H; Wan J; Huang X; Tang Y; Xiao C; Xu H; Yang X; Li Z
Nanoscale; 2018 Jun; 10(22):10514-10527. PubMed ID: 29799599
[TBL] [Abstract][Full Text] [Related]
34. Transarterial Infusion of iRGD-Modified ZrO
Xie Y; Qi X; Xu K; Meng X; Chen X; Wang F; Zhong H
J Vasc Interv Radiol; 2019 Dec; 30(12):2026-2035.e2. PubMed ID: 31590966
[TBL] [Abstract][Full Text] [Related]
35. Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles.
Chen R; Ni S; Chen W; Liu M; Feng J; Hu K
Int J Nanomedicine; 2021; 16():5265-5279. PubMed ID: 34376979
[TBL] [Abstract][Full Text] [Related]
36. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
37. Coadministration of iRGD with Multistage Responsive Nanoparticles Enhanced Tumor Targeting and Penetration Abilities for Breast Cancer Therapy.
Hu C; Yang X; Liu R; Ruan S; Zhou Y; Xiao W; Yu W; Yang C; Gao H
ACS Appl Mater Interfaces; 2018 Jul; 10(26):22571-22579. PubMed ID: 29878758
[TBL] [Abstract][Full Text] [Related]
38. Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma.
Deng C; Zhang Q; Fu Y; Sun X; Gong T; Zhang Z
ACS Appl Mater Interfaces; 2017 Jan; 9(2):1280-1292. PubMed ID: 28009503
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
40. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
